Literature DB >> 11514910

Immunopathogenesis of scleroderma--evolving concepts.

A N Sapadin1, A C Esser, R Fleischmajer.   

Abstract

Scleroderma, or systemic sclerosis, is a connective tissue disease which may affect various organ systems including skin, lungs, gastrointestinal tract, cardiovascular system and kidneys. While the etiology is not clear, it is currently believed that scleroderma may represent an autoimmune response to an unknown antigen. In this regard, there is evidence that both humoral and cellular immunity may play roles. The pathophysiology is complex and consists of three major features: (1) vascular damage; (2) mononuclear cellular infiltrates; and (3) massive deposition of newly synthesized connective tissue, mainly collagen. The major pathologic features of scleroderma and the roles of humoral and cellular immunity in its pathogenesis are reviewed and summarized.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11514910

Source DB:  PubMed          Journal:  Mt Sinai J Med        ISSN: 0027-2507


  9 in total

Review 1.  Cellular and molecular aspects of vascular dysfunction in systemic sclerosis.

Authors:  Maria Trojanowska
Journal:  Nat Rev Rheumatol       Date:  2010-06-29       Impact factor: 20.543

2.  A portable dermatoscope for easy, rapid examination of periungual nailfold capillary changes in patients with systemic sclerosis.

Authors:  Eiji Muroi; Toshihide Hara; Koichi Yanaba; Fumihide Ogawa; Ayumi Yoshizaki; Motoi Takenaka; Kazuhiro Shimizu; Shinichi Sato
Journal:  Rheumatol Int       Date:  2010-05-27       Impact factor: 2.631

3.  Organ involvement in Argentinian systemic sclerosis patients with "late" pattern as compared to patients with "early/active" pattern by nailfold capillaroscopy.

Authors:  Lucila Marino Claverie; Elizabeth Knobel; Lorena Takashima; Lorena Techera; Marina Oliver; Paula Gonzalez; Félix E Romanini; María L Fonseca; Marta N Mamani
Journal:  Clin Rheumatol       Date:  2013-02-16       Impact factor: 2.980

Review 4.  Systemic and localized scleroderma in children: current and future treatment options.

Authors:  Margalit E Rosenkranz; Lucila M A Agle; Petros Efthimiou; Thomas J A Lehman
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

5.  The use of streptolysin o for the treatment of scars, adhesions and fibrosis: initial investigations using murine models of scleroderma.

Authors:  Stephen W Mamber; Vit Long; Ryan G Rhodes; Sunthorn Pond-Tor; Lyn R Wheeler; Kellie Fredericks; Brian Vanscoy; Jean-Frederic Sauniere; Remy Steinschneider; Jean-Claude Laurent; John McMichael
Journal:  Nonlinearity Biol Toxicol Med       Date:  2004-04

6.  Transcription factor Fli1 regulates collagen fibrillogenesis in mouse skin.

Authors:  Yoshihide Asano; Margaret Markiewicz; Masahide Kubo; Gabor Szalai; Dennis K Watson; Maria Trojanowska
Journal:  Mol Cell Biol       Date:  2008-11-10       Impact factor: 4.272

7.  Evaluation of serum concentrations of the selected cytokines in patients with localized scleroderma.

Authors:  Jolanta Budzyńska-Włodarczyk; Małgorzata M Michalska-Jakubus; Małgorzata Kowal; Dorota Krasowska
Journal:  Postepy Dermatol Alergol       Date:  2016-02-29       Impact factor: 1.837

8.  Capillary regeneration in scleroderma: stem cell therapy reverses phenotype?

Authors:  Jo N Fleming; Richard A Nash; D O McLeod; David F Fiorentino; Howard M Shulman; M Kari Connolly; Jerry A Molitor; Gretchen Henstorf; Robert Lafyatis; David K Pritchard; Lawrence D Adams; Daniel E Furst; Stephen M Schwartz
Journal:  PLoS One       Date:  2008-01-16       Impact factor: 3.240

Review 9.  The role of type 1 interferon in systemic sclerosis.

Authors:  Minghua Wu; Shervin Assassi
Journal:  Front Immunol       Date:  2013-09-06       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.